Renal Denervation: Patient Selection and When to Refer
- PMID: 40499671
- DOI: 10.1016/j.amjcard.2025.06.009
Renal Denervation: Patient Selection and When to Refer
Abstract
The US FDA approved Renal Denervation for hypertension treatment in November 2023. Regardless of the methodology used to denervate, most but not all people had a clinically significant reduction in blood pressure in the months following the procedure. In this review we summarize the current data informing patient selection, and provide guidance on when to refer potential patients for consideration of this therapy in the management of uncontrolled hypertension.
Keywords: hypertension; patient referral; patient selection; renal denervation.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RV – Consultant to Medtronic and Mineralys Therapeutics. MJB – Steering committee member for Recor Medical; Consultant to Medtronic. NDLF – Consultant to Recor Medical, Aktiia, Alnylam, Astra Zeneca and Medtronic; Research funding from Recor Medical.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical